NYSE · ACH

Accendra Health, Inc.

$3.22 +$0.08 (+2.55%) 1D Market open

Key Metrics

$240.47M
Market cap
P/E · TTM
$757.76M
Revenue · TTM
−$1.08B
Net income
EPS · TTM $-14.00
Dividend yield
Free cash flow
Beta · 1Y 1.54
EBITDA · TTM $131.99M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 11
    The stock moved +17.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 11
  • Jun 8
    From its May 11 high, the share price fell 34%.

    Peak close $3.89 on May 11; trough close $2.55 on Jun 8. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -34%
  • May 12
    The stock moved -17.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 12

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$240.47M
Enterprise value$2.01B
Shares outstanding76.6M
52-wk range$1.84 – $4.69
Avg volume · 20D932.9K
Net cash −$1.77B
Book value / share$-6.01
IndustryWholesale-Medical, Dental & Hospital Equipment & Supplies
ExchangeNYSE
About Accendra Health, Inc.
IPO dateJan 2, 1973
Employees6500

Accendra Health Inc is a nationwide provider of products, technology, and services that support health beyond the hospital by connecting patients, providers, and insurers.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S0.32
P/FCF
EV/EBITDA15.20
EV/Sales2.65
Graham №

Profitability

Gross
Operating -11.0%
Net -142.8%
FCF
ROE / ROIC -2,154.3% · -6.5%

Financial Health

Current ratio0.49
Quick ratio0.43
Debt / equity-4.53
Debt / EBITDA 15.93
Net cash −$1.77B
Working capital−$614.60M

Cash Flow · TTM

Operating CF −$116.80M
Capex
Free cash flow
Buybacks $8.68M
Dividends paid
Shareholder yield 3.6%

Piotroski F-Score

1 / 9
Weak fundamentals · 1 of 9 signals passing

Altman Z-Score

-0.7
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings